Eisai Launches At-Home Leqembi Iqlik for Early Alzheimer's Treatment
Event summary
- Eisai's Leqembi Iqlik®, a subcutaneous injection for early Alzheimer's, launched in the US on August 24, 2026, following FDA approval on July 13, 2026.
- The autoinjector allows at-home dosing, replacing IV infusions for initiation and maintenance therapy.
- Regimen: 500 mg once weekly, delivered as two 250 mg injections, each in ~15 seconds.
- Leqembi is approved in 53 countries, with regulatory reviews ongoing in 6 more.
- BioArctic holds commercialization rights in the Nordic region and receives milestone payments and royalties on global sales.
The big picture
The launch of Leqembi Iqlik marks a shift toward patient-centric care in Alzheimer's treatment, reducing reliance on clinical settings. Eisai's strategic alliance with BioArctic and Biogen underscores the industry's push for innovative, accessible therapies. With Leqembi approved in 53 countries and regulatory reviews ongoing, the treatment's global reach could expand significantly, reinforcing Eisai's leadership in neurodegenerative disease therapeutics.
What we're watching
- Market Adoption
- The pace at which patients and caregivers adopt at-home dosing could determine Leqembi Iqlik's market penetration.
- Regulatory Expansion
- Whether Eisai secures approvals in the remaining 6 countries under review will impact global revenue potential.
- Competitive Dynamics
- How BioArctic and Eisai's partnership scales commercialization in the Nordics and other regions.